Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

Article Tools

• Email

  Thank you for your interest in spreading the word about Science Translational Medicine.

  NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

  Your Email

  Your Name

  Send To

  Enter multiple addresses on separate lines or separate them with commas.

  You are going to email the following Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

  Message Subject (Your Name) has forwarded a page to you from Science Translational Medicine

  Message Body (Your Name) thought you would like to see this page from the Science Translational Medicine web site.

  Your Personal Message

  CAPTCHA

  This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

  Send Message
• Download Powerpoint
• Print
• Alerts

  Please log in to add an alert for this article.

  Log In with your AAAS ID

  Sign In to Email Alerts with your Email Address

  Email

  Log in
• Citation tools

  Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

  By Sébastien Jacquemont, Aurore Curie, Vincent des Portes, Maria Giulia Torrioli, Elizabeth Berry-Kravis, Randi J. Hagerman, Feliciano J. Ramos, Kim Cornish, Yunsheng He, Charles Paulding, Giovanni Neri, Fei Chen, Nouchine Hadjikhani, Danielle Martinet, Joanne Meyer, Jacques S. Beckmann, Karine Delange, Amandine Brun, Gerald Bussy, Fabrizio Gasparini, Talita Hilse, Annette Floesser, Janice Branson, Graeme Bilbe, Donald Johns, Baltazar Gomez-Mancilla

  Science Translational Medicine05 Jan 2011 : 64ra1

  An antagonist for the metabotropic glutamate receptor may improve symptoms in patients with fragile X syndrome whose FMR1 promoters are fully methylated.

  Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
• Share

  Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

  By Sébastien Jacquemont, Aurore Curie, Vincent des Portes, Maria Giulia Torrioli, Elizabeth Berry-Kravis, Randi J. Hagerman, Feliciano J. Ramos, Kim Cornish, Yunsheng He, Charles Paulding, Giovanni Neri, Fei Chen, Nouchine Hadjikhani, Danielle Martinet, Joanne Meyer, Jacques S. Beckmann, Karine Delange, Amandine Brun, Gerald Bussy, Fabrizio Gasparini, Talita Hilse, Annette Floesser, Janice Branson, Graeme Bilbe, Donald Johns, Baltazar Gomez-Mancilla

  Science Translational Medicine05 Jan 2011 : 64ra1

  An antagonist for the metabotropic glutamate receptor may improve symptoms in patients with fragile X syndrome whose FMR1 promoters are fully methylated.

  Share This Article: Copy